HD-OPM Archive
Topics › Gut microbiome

Imidazole propionate, a gut-bacterial metabolite, drives atherosclerosis in mice

Gokhan Can · Jul 24, 2025 · ♥ 14 reactions · 4 comments · original Facebook post
Gut microbiomeInflammation & CRPBlood vessels, circulation & endothelium
AI summary & key facts

A Nature paper reports that imidazole propionate (ImP) is independently associated with cardiovascular disease and causes atherosclerosis in mice through inflammation via the I1 imidazoline receptor. Blocking that receptor could become a cholesterol-independent therapy.

According to a recent article in Nature by a multinational research team, the bacterial metabolite imidazole propionate (ImP) has been identified as a significant and direct driver of atherosclerosis. This molecule, already linked to diabetes and metabolic syndrome, was found to be independently associated with cardiovascular disease, separate from traditional risk factors. Experiments in mice revealed that ImP causes atherosclerosis independent of cholesterol levels by inducing inflammation through a specific signaling pathway involving the I1 imidazoline receptor (I1R). This discovery suggests that blocking the I1R could become a novel, cholesterol-independent therapeutic approach for preventing heart disease, potentially revolutionizing the understanding of metabolic disease and underscoring the profound impact of the gut microbiome on human health.

PaperNew cause of atherosclerosisNow here’s something that could rework the way that we think about atherosclerosis. A large multinational team has reported in Nature that a simple molecule produced by human-associated bacteria seems to be a driver for cardiovascular risk. The molecule is imidazole propionate (ImP), which is a me...science.org

Research cited

#atherosclerosis#mice#cholesterol#metabolicsyndrome#cardiovasculardisease#riskfactors#heartdisease#diabetes
← newer: Gut-microbe D-lactate raises blood sugar and liver fat; an oolder: Imidazole propionate: how gut bacteria make it from histidin →